End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.34 CNY | +0.36% | -2.57% | -10.90% |
16/05 | Hisun Pharma's Veterinary Arm Gets Nod to Market Selamectin Drops | MT |
29/04 | Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is not the most generous with respect to shareholders' compensation.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.90% | 1.36B | - | ||
+32.09% | 694B | C+ | ||
+29.39% | 593B | B | ||
-1.34% | 371B | C+ | ||
+20.34% | 331B | B- | ||
+7.39% | 290B | C+ | ||
+14.25% | 239B | B+ | ||
-3.03% | 209B | A+ | ||
+10.02% | 209B | B- | ||
+8.49% | 169B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 600267 Stock
- Ratings Zhejiang Hisun Pharmaceutical Co., Ltd.